Post
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
Vivavision Biotech has reported that its Phase IIa first in human study of VVN539 Ophthalmic Solution in the US has met …
Chimeric launches Phase IB trial of glioblastoma multiforme therapy
Chimeric Therapeutics has launched a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy to treat …
Elicio reports positive interim clinical data of cancer immunotherapy study
Elicio Therapeutics has reported positive interim clinical data from its ongoing Phase I AMPLIFY-201 study evaluating its cancer immunotherapy, ELI-002, …
BioInvent receives IND approval for study of anti-TNFR2 antibody
BioInvent International has received investigational new drug (IND) approval to initiate a Phase I/IIa study of BI-1910. Compared to BioInvent’s BI-1808 …
Leading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
First patient enrolled in pulmonary hypertension reduction device study
Paris-based Gradient Denervation Technologies has performed the first procedure in its first-in-human clinical study for a pulmonary hypertension device. The …
Innovent and Merck to carry out cancer combination therapy trial
Innovent Biologics and Merck have entered a clinical trial collaboration and supply agreement for the combination therapy of IBI351 (GFH925) …
YS Biopharma receives approval for vaccine trial in Philippines
The Food and Drug Administration (FDA) of the Philippines has given approval to biopharmaceutical firm YS Biopharma to begin a …
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts …
AstraZeneca abandons inflammatory bowel disease drug
AstraZeneca’s brazikumab inflammatory bowel disease (IBD) development programme has been discontinued due to trial delays. Brazikumab, an anti-IL-23 monoclonal antibody, was …
Athersys begins enrolment in final cohort of MultiStem trial
US-based biotechnology company Athersys has begun enrolling patients in the third and final cohort of a Phase II study of …
Sirnaomics doses first patient in anticoagulant treatment trial
US-based biopharmaceutical company Sirnaomics has dosed the first patient in a Phase I clinical trial of STP122G, an RNAi drug …
Saudi astronaut concludes space experiments on inflammatory diseases
Saudi Arabia’s astronaut Rayyanah Barnawi has completed the implementation of King Faisal Specialist Hospital and Research Center (KFSH&RC) cell science …
Sensei Biotherapeutics doses patients in tumour therapy trial
US-based biotechnology company Sensei Biotherapeutics has dosed the first patient in a Phase I/II clinical trial of SNS-101 to treat …
Clearside opens enrolment in Phase IIb trial of wet AMD therapy
US-based biopharmaceutical company Clearside Biomedical has begun enrolling patients in its Phase IIb trial of CLS-AX (axitinib injectable suspension). The multi-centre …